This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ESMO-Asia, Singapore 22-24 November 2019

Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients with advanced solid tumors​

Kentaro Yamazaki, Takafumi Koyama, Toshio Shimizu, Toshiaki Takahashi, Junichiro Watanabe, Yuko Tanaka, Hiroshi Myobudani, Noboru Yamamoto

yamazaki_1336.12_esmo_asia_2019.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

RELATED INFORMATION

VEGF/Ang2 inhibitor

BI 836880 is a humanised bispecific nanobody® comprising blocking domains for both VEGF and Ang2

PD-1 inhibitor (BI 754091)

BI 754091 is a PD-1 inhibitor that binds to the PD-1 receptor, thereby blocking signalling downstream from PD-1 and allowing T cell-mediated tumour cell destruction

RELATED INFORMATION

VEGF/Ang2 inhibitor

BI 836880 is a humanised bispecific nanobody® comprising blocking domains for both VEGF and Ang2

PD-1 inhibitor (BI 754091)

BI 754091 is a PD-1 inhibitor that binds to the PD-1 receptor, thereby blocking signalling downstream from PD-1 and allowing T cell-mediated tumour cell destruction
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

image